{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:34:48Z","timestamp":1786703688887,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01038-8","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:23:18Z","timestamp":1761218598000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-9030","authenticated-orcid":false,"given":"Ja Yoon","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon S.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-1896","authenticated-orcid":false,"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"1038_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1038_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed 23 Sep 2025)."},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","volume":"96","author":"RS Hubert","year":"1999","unstructured":"Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA. 1999;96:14523\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1038_CR4","doi-asserted-by":"publisher","first-page":"53.e23","DOI":"10.1016\/j.urolonc.2013.08.028","volume":"32","author":"IM Gomes","year":"2014","unstructured":"Gomes IM, Arinto P, Lopes C, Santos CR, Maia CJ. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol. 2014;32:53.e23\u20139.","journal-title":"Urol Oncol"},{"key":"1038_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.","journal-title":"Science"},{"key":"1038_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1285661","volume":"13","author":"H Nakamura","year":"2023","unstructured":"Nakamura H, Arihara Y, Takada K. Targeting STEAP1 as an anticancer strategy. Front Oncol. 2023;13:1285661.","journal-title":"Front Oncol"},{"key":"1038_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041.","journal-title":"Nat Commun"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/his.12226","volume":"63","author":"SM Ihlaseh-Catalano","year":"2013","unstructured":"Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, Domingues MA, Trindade Filho JC, de Camargo JL, et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma. Histopathology. 2013;63:678\u201385.","journal-title":"Histopathology"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","volume":"37","author":"DC Danila","year":"2019","unstructured":"Danila DC, Szmulewitz RZ, Vaishampayan UN, Higano CS, Gilbert HN, Brunstein F, et al. Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:3518\u201327.","journal-title":"J Clin Oncol"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","volume":"14","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Darpo B, Prawira A, Aggarwal R, Williams K, Liao R, et al. AMG 509 (Xaluritamig), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer. Cancer Discov. 2024;14:90\u2013103.","journal-title":"Cancer Discov"},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/1541-7786.MCR-11-0281","volume":"10","author":"IM Gomes","year":"2012","unstructured":"Gomes IM, Maia CJ, Santos CR. STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res. 2012;10:573\u201387.","journal-title":"Mol Cancer Res"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.yexcr.2013.07.025","volume":"319","author":"T Yamamoto","year":"2013","unstructured":"Yamamoto T, Tamai Y, Tanaka M, Yamazaki Y, Nakano M, Kanai Y, et al. Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication. Exp Cell Res. 2013;319:2617\u201326.","journal-title":"Exp Cell Res"},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/boc.201200027","volume":"104","author":"TGP Grunewald","year":"2012","unstructured":"Grunewald TGP, Bach H, Cossarizza A, Matsumoto I. The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol Cell. 2012;104:641\u201357.","journal-title":"Biol Cell"},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood-2006-02-003681","volume":"108","author":"RS Ohgami","year":"2006","unstructured":"Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006;108:1388\u201394.","journal-title":"Blood"},{"key":"1038_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.752426","volume":"9","author":"WJ Chen","year":"2021","unstructured":"Chen WJ, Lin J, Luo L, Chen M, Liu Y, Zhao Z, et al. Regulatory roles of six-transmembrane epithelial antigen of the prostate family members in the occurrence and development of malignant tumors. Front Cell Dev Biol. 2021;9:752426.","journal-title":"Front Cell Dev Biol"},{"key":"1038_CR16","doi-asserted-by":"publisher","unstructured":"Oosterheert W, Marchese S, Mattevi A. Structure, function and mechanism of six-transmembrane epithelial antigen of the prostate (STEAP) enzymes: insights into a transmembrane oxidoreductase family related to NADPH oxidases. In: Structure and function of membrane proteins. Springer; 2023. pp. 521\u201334. https:\/\/doi.org\/10.1007\/978-3-031-23752-2_31.","DOI":"10.1007\/978-3-031-23752-2_31"},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1074\/jbc.RA120.013690","volume":"295","author":"W Oosterheert","year":"2020","unstructured":"Oosterheert W, Gros P. Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1). J Biol Chem. 2020;295:9502\u201312.","journal-title":"J Biol Chem"},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc3495","volume":"13","author":"SV Torti","year":"2013","unstructured":"Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342\u201355.","journal-title":"Nat Rev Cancer"},{"key":"1038_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbi.2005.12.009","volume":"160","author":"M Valko","year":"2006","unstructured":"Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1\u201340.","journal-title":"Chem Biol Interact"},{"key":"1038_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1541-7786.MCR-11-0524","volume":"10","author":"TGP Grunewald","year":"2012","unstructured":"Grunewald TGP, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 2012;10:52\u201365.","journal-title":"Mol Cancer Res"},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2008.12.011","volume":"282","author":"L Khandrika","year":"2009","unstructured":"Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009;282:125\u201336.","journal-title":"Cancer Lett"},{"key":"1038_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41417-018-0056-8","volume":"26","author":"H Nakamura","year":"2019","unstructured":"Nakamura H, Morimoto Y, Komatsu T, Li B, Takano N, Arihara Y, et al. Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. Cancer Gene Ther. 2019;26:313\u201322.","journal-title":"Cancer Gene Ther"},{"key":"1038_CR23","first-page":"641","volume":"88","author":"Y Pan","year":"2008","unstructured":"Pan Y, Li Y, Guo L, Zhao Y, Zhao X. [Influence of expression of six transmembrane epithelial antigen of the prostate-1 on intracellular reactive oxygen species level and cell growth: an in vitro experiment]. Zhonghua Yi Xue Za Zhi. 2008;88:641\u20134.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1038_CR24","unstructured":"Huo SF, Zhu WT, Wu H, Jian B, Zhao ZY, Feng JY, et al. STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2\/STAT3 signaling pathway. Biosci Rep. 2020;40:BSR20193169."},{"key":"1038_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8810785","volume":"2020","author":"J Zhu","year":"2020","unstructured":"Zhu J, Xu S, Gao W, Dong J, Xu B, Qin Y, et al. The molecular mechanisms of regulating oxidative stress-induced ferroptosis and therapeutic strategy in tumors. Oxid Med Cell Longev. 2020;2020:8810785.","journal-title":"Oxid Med Cell Longev"},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1007\/s11033-023-08403-7","volume":"50","author":"X Zou","year":"2023","unstructured":"Zou X, Peng H, Zhou A, Gong X, Song X, Wu W, et al. Inhibition of STEAP1 ameliorates inflammation and ferroptosis of acute lung injury caused by sepsis in LPS-induced human pulmonary microvascular endothelial cells. Mol Biol Rep. 2023;50:5667\u201374.","journal-title":"Mol Biol Rep"},{"key":"1038_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41420-023-01430-0","volume":"9","author":"J Liang","year":"2023","unstructured":"Liang J, Gao Z, Wang Y, Liu X, Wei B, Fan L, et al. Ferroptosis landscape in prostate cancer from molecular and metabolic perspective. Cell Death Discov. 2023;9:128.","journal-title":"Cell Death Discov"},{"key":"1038_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-024-00869-9","volume":"21","author":"PHA Cao","year":"2024","unstructured":"Cao PHA, Skovbakke SL, Christensen JK, Bostr\u00f6m PJ, R\u00f8rth M, Nordentoft I, et al. Unlocking ferroptosis in prostate cancer \u2013 the road to novel therapies and imaging markers. Nat Rev Urol. 2024;21:615\u201337.","journal-title":"Nat Rev Urol"},{"key":"1038_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119522","volume":"1870","author":"SM Rocha","year":"2023","unstructured":"Rocha SM, Santos FM, Socorro S, Passarinha LA, Maia CJ. Proteomic analysis of STEAP1 knockdown in human LNCaP prostate cancer cells. Biochim Biophys Acta Mol Cell Res. 2023;1870:119522.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1038_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00418-020-01877-7","volume":"154","author":"Z Jiao","year":"2020","unstructured":"Jiao Z, Wang S, Xu Z, Ren F, Li Y, Liu X, et al. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition. Histochem Cell Biol. 2020;154:215\u201330.","journal-title":"Histochem Cell Biol"},{"key":"1038_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1100-0","volume":"35","author":"IM Gomes","year":"2018","unstructured":"Gomes IM, Rocha SM, Gaspar C, Alho I, Gouveia AM, Oliveira MJ, et al. Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens. Med Oncol. 2018;35:40.","journal-title":"Med Oncol"},{"key":"1038_CR32","doi-asserted-by":"crossref","unstructured":"Rocha SM, Alho I, Gaspar C, Arinto P, Maia CJ, Gomes IM, et al. STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide. Mol Med Rep. 2023;27:52.","DOI":"10.3892\/mmr.2023.12939"},{"key":"1038_CR33","doi-asserted-by":"crossref","unstructured":"Lin TY, Park JA, Long A, Guo HF, Cheung NKV. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. J Immunother Cancer. 2021;9:e003114.","DOI":"10.1136\/jitc-2021-003114"},{"key":"1038_CR34","doi-asserted-by":"crossref","unstructured":"Rocha SM, Socorro S, Passarinha LA, Maia CJ. Comprehensive landscape of STEAP family members expression in human cancers: Unraveling the potential usefulness in clinical practice using integrated bioinformatics analysis. Data. 2022;7:64.","DOI":"10.3390\/data7050064"},{"key":"1038_CR35","doi-asserted-by":"crossref","unstructured":"Rocha SM, Gouveia MJ, Alho I, Passarinha LA, Maia CJ, Gomes IM, et al. STEAP1 knockdown decreases the sensitivity of prostate cancer cells to paclitaxel, docetaxel and cabazitaxel. Int J Mol Sci. 2023;24:6643.","DOI":"10.3390\/ijms24076643"},{"key":"1038_CR36","doi-asserted-by":"publisher","unstructured":"Bizzaro CL, D\u2019Agostino S, Chen X, Shahid Z, Li M, Almeida L, et al. Exploring STEAP1 expression in prostate cancer cells in response to androgen deprivation and in small extracellular vesicles. Mol Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1541-7786.MCR-24-0903.","DOI":"10.1158\/1541-7786.MCR-24-0903"},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","volume":"60","author":"JA Carrasquillo","year":"2019","unstructured":"Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming M, Smith-Jones PM, et al. Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody. J Nucl Med. 2019;60:1517\u201323.","journal-title":"J Nucl Med"},{"key":"1038_CR38","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41391-021-00319-2","volume":"24","author":"K Khanna","year":"2021","unstructured":"Khanna K, Salmond N, Lynn KS, Leong HS, Williams KC. Clinical significance of STEAP1 extracellular vesicles in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:802\u201311.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1038_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17975\/sfj-2017-010","volume":"3","author":"AC Poon","year":"2017","unstructured":"Poon AC, Tang Y, Li C, Wu S. Nanoscale flow cytometry of patient plasma for the detection of prostate cancer-associated extracellular vesicles. STEM Fellowsh J. 2017;3:1\u20132.","journal-title":"STEM Fellowsh J"},{"key":"1038_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1538-7445.AM2024-61","volume":"84","author":"M Sheng","year":"2024","unstructured":"Sheng M, Lee JH, Kim S, Patel S, Wong C, Chan J, et al. Abstract 61: a novel immunotherapy for metastatic prostate cancer: a monoclonal antibody that can bind both STEAP1 and STEAP2. Cancer Res. 2024;84:61\u201361.","journal-title":"Cancer Res"},{"key":"1038_CR41","unstructured":"OncologyPipeline. Vandortuzumab vedotin discontinued after Phase I trial in 2016. 2023. https:\/\/www.oncologypipeline.com\/apexonco\/esmo-2023-amgens-steap1-project-spurs-cautious-optimism."},{"key":"1038_CR42","doi-asserted-by":"publisher","first-page":"e17161","DOI":"10.1200\/JCO.2025.43.16_suppl.e17161","volume":"43","author":"J Yu","year":"2025","unstructured":"Yu J, Chen L, Zhou P, Li D, Wang J, Huang Y, et al. The anti-STEAP1\/PSMA ADC, DXC008: assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties. J Clin Oncol. 2025;43:e17161.","journal-title":"J Clin Oncol"},{"key":"1038_CR43","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhou X, Pan Y, Li M, Huang H, Wang Y, et al. The role of STEAP1 in prostate cancer: implications for diagnosis and therapeutic strategies. Biomedicines. 2025;13:794","DOI":"10.3390\/biomedicines13040794"},{"key":"1038_CR44","unstructured":"A Phase I, open-label, multicenter, first-in-human, dose escalation and expansion clinical study to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of DXC008 in patients with prostate cancer and other solid tumors (such as Ewing sarcoma). 2025. ClinicalTrials.gov identifier: NCT06926283. https:\/\/clinicaltrials.gov\/study\/NCT06926283 (accessed 23 Sep 2025)."},{"key":"1038_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Aggarwal R, Petrylak DP, Tagawa ST, Vogelzang NJ, Yu EY, et al. Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov. 2024;14:76\u201389.","journal-title":"Cancer Discov"},{"key":"1038_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1038_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334.","journal-title":"Nat Med"},{"key":"1038_CR48","first-page":"A755","volume":"11","author":"MN Stein","year":"2023","unstructured":"Stein MN, Frank L, Petrylak DP, Heath EI, Yu EY, George DJ, et al. Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: a clinical trial in progress. J Immunother Cancer. 2023;11:A755.","journal-title":"J Immunother Cancer"},{"key":"1038_CR49","unstructured":"Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer. 2025. ClinicalTrials.gov identifier: NCT05617040. https:\/\/www.clinicaltrials.gov\/study\/NCT05617040 (accessed 23 Sep 2025)."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01038-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:04:12Z","timestamp":1786701852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01038-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01038-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}